The autoimmune disease diagnostics market was valued at USD 4,253.30 million in 2021 and is projected to reach USD 6,298.98 million by 2027 registering a CAGR of nearly 6.8% during the forecast period.
The first wave of the COVID-19 pandemic has disrupted almost all areas of health care services to some extent throughout the world. The negative impact of COVID-19 on patients with autoimmune diseases has also been recognized. According to an article titled "The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned," published in October 2021, a decrease in the number of autoantibody tests was observed in all European countries in the year 2020 compared to 2019. All autoantibody tests saw a 13% decrease, ranging from 1.4% in Switzerland to 25.5% in the United States (Greece). The decrease was most pronounced in all countries during the first wave of the pandemic (March-May 2020), with an overall decrease of 45.2% in those three months. The decrease was less pronounced(6.8%) in the second wave of the pandemic (October-December 2020).
The rising autoimmune diseases are the primary factor behind the market growth. According to scientists at the National Institutes of Health and their collaborators, autoimmunity, a condition in which the body’s immune system reacts with components of its cells, appears to be increasing in the United States. Also, according to the article published in January 2022, Autoimmune diseases are becoming more prevalent worldwide. The global spread of Western diets is linked to higher levels of autoimmune disease. As per the same source, Tens of millions of people develop autoimmune diseases in the US alone, and the number of cases has been increasing in recent decades. Thus, the increasing number of autoimmune diseases is driving the market growth.
The rising awareness about autoimmune diseases through research, education, support, and advocacy programs is a keycrucialctor boosting the usage rates of autoimmune disease diagnostics globally. Government organizations and NGOs aim to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in education, public awareness, research, and patient services in a practical, ethical, and efficient manner. The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, and technological advancements, are driving the autoimmune disease diagnostics market. However, the slow turnaround time of the diagnosis and high frequency of false results are hindering the growth of the autoimmune disease diagnostics market.
Early detection of autoimmune rheumatic diseases (ARDs) is critical for effective treatment and a better prognosis. On a global scale, the coronavirus disease 2019 (COVID-19) pandemic has significantly changed clinical practice. According to an article published in February 2022 titled "Impact of the COVID-19 Pandemic on the Appropriateness of Diagnostic Pathways of Autoimmune Rheumatic Diseases," the volume of autoimmunity laboratory tests in 2020 was significantly lower than in 2019. There was also a significant reduction in the number of first rheumatological visits and diagnoses.
Additionally, according to medical records and laboratory data collected from San Carlo Hospital in Basilicata, Italy, between January and December 2020 and compared to the same period in 2019, there was a significant decrease in autoimmunity tests during the pandemic period when compared to the previous year (9912 vs. 14100, respectively). General practitioners (GPs) ordered 70% of trials in 2020, followed by other specialists (20%) and rheumatologists (10%). Antinuclear antibodies (ANA), anti-extractable nuclear antigen (anti-ENA), anti-double-stranded DNA (anti-dsDNA), rheumatoid factor (RF), and anti-neutrophil cytoplasmic antibody all had 1.5 times fewer samples. Compared to the pre-pandemic period (1272 vs. 2336), rheumatological visits decreased by 48 % in 2020, with the most significant drops occurring in March, April, and May.
Rheumatoid arthritis (RA) is an autoimmune disease that mainly attacks the synovial tissues within the joints. The disease predominantly affects elderly patients. The aging population and technological advancements in immunofluorescence and proteomics technologies will further enhance the rheumatoid arthritis diagnosis influencing the segment growth.
The rising prevalence of diseases such as rheumatoid arthritis and Hashimoto’s thyroiditis and the presence of favorable government regulations will significantly impact the autoimmune disease diagnostics market growth. As per the Global RA Network, 2021, More than 350 million people have arthritis globally. The demand for better and more precise diagnostic methods, along with the increasing prevalence, is expected to increase over the forecast period.
The COVID-19 pandemic significantly impacted the diagnosis of autoimmune diseases and clinical laboratory operations far beyond shortages of reagents and supplies. The increased workload forced laboratories to mobilize personnel and resources to support SARS-CoV-2 testing, affecting diagnostic testing of autoimmune diseases. Besides, people were also reluctant to visit the clinics and diagnostics centers during the 1stand 2nd wave of the coronavirus pandemic.
Asia-Pacific is anticipated to exhibit extensive market growth over the forecast period, owing to rising disposable income and increasing patient pool in emerging countries. Furthermore, growing awareness regarding the benefits of early and accurate diagnosis of autoimmune diseases to seek the proper treatment, rising development of healthcare infrastructure, and increasing healthcare expenditure are likely to boost the growth of the autoimmune disease diagnostics market in the Asia-Pacific region.
According to an article published by Janssen Asia Pacific, a division of Johnson & Johnson Pte. Ltd., autoimmune, inflammatory, and pulmonary diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are on the rise in the Asia Pacific. The region already has the world's highest burden of chronic obstructive pulmonary disease (COPD), as well as the highest prevalence of systemic lupus erythematosus (SLE) in China and Southeast Asia. Hence, this will likely create demand for diagnostics in the coming years.
The Autoimmune Disease Diagnostics Market is fragmented and competitive. The market comprises significant market players, and these players are focusing on R&D activities and effective growth strategies. Recently, a few diagnostic companies entered into strategic partnerships with hospitals. This trend is expected to continue over the next few years to meet the high volume of patient needs across different regions.
This product will be delivered within 2 business days.
The first wave of the COVID-19 pandemic has disrupted almost all areas of health care services to some extent throughout the world. The negative impact of COVID-19 on patients with autoimmune diseases has also been recognized. According to an article titled "The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned," published in October 2021, a decrease in the number of autoantibody tests was observed in all European countries in the year 2020 compared to 2019. All autoantibody tests saw a 13% decrease, ranging from 1.4% in Switzerland to 25.5% in the United States (Greece). The decrease was most pronounced in all countries during the first wave of the pandemic (March-May 2020), with an overall decrease of 45.2% in those three months. The decrease was less pronounced(6.8%) in the second wave of the pandemic (October-December 2020).
The rising autoimmune diseases are the primary factor behind the market growth. According to scientists at the National Institutes of Health and their collaborators, autoimmunity, a condition in which the body’s immune system reacts with components of its cells, appears to be increasing in the United States. Also, according to the article published in January 2022, Autoimmune diseases are becoming more prevalent worldwide. The global spread of Western diets is linked to higher levels of autoimmune disease. As per the same source, Tens of millions of people develop autoimmune diseases in the US alone, and the number of cases has been increasing in recent decades. Thus, the increasing number of autoimmune diseases is driving the market growth.
The rising awareness about autoimmune diseases through research, education, support, and advocacy programs is a keycrucialctor boosting the usage rates of autoimmune disease diagnostics globally. Government organizations and NGOs aim to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in education, public awareness, research, and patient services in a practical, ethical, and efficient manner. The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, and technological advancements, are driving the autoimmune disease diagnostics market. However, the slow turnaround time of the diagnosis and high frequency of false results are hindering the growth of the autoimmune disease diagnostics market.
Key Market Trends
Rheumatoid Arthritis Segment is Expected to Hold a Major Market Share in the Autoimmune Disease Diagnostics Market
Early detection of autoimmune rheumatic diseases (ARDs) is critical for effective treatment and a better prognosis. On a global scale, the coronavirus disease 2019 (COVID-19) pandemic has significantly changed clinical practice. According to an article published in February 2022 titled "Impact of the COVID-19 Pandemic on the Appropriateness of Diagnostic Pathways of Autoimmune Rheumatic Diseases," the volume of autoimmunity laboratory tests in 2020 was significantly lower than in 2019. There was also a significant reduction in the number of first rheumatological visits and diagnoses.
Additionally, according to medical records and laboratory data collected from San Carlo Hospital in Basilicata, Italy, between January and December 2020 and compared to the same period in 2019, there was a significant decrease in autoimmunity tests during the pandemic period when compared to the previous year (9912 vs. 14100, respectively). General practitioners (GPs) ordered 70% of trials in 2020, followed by other specialists (20%) and rheumatologists (10%). Antinuclear antibodies (ANA), anti-extractable nuclear antigen (anti-ENA), anti-double-stranded DNA (anti-dsDNA), rheumatoid factor (RF), and anti-neutrophil cytoplasmic antibody all had 1.5 times fewer samples. Compared to the pre-pandemic period (1272 vs. 2336), rheumatological visits decreased by 48 % in 2020, with the most significant drops occurring in March, April, and May.
Rheumatoid arthritis (RA) is an autoimmune disease that mainly attacks the synovial tissues within the joints. The disease predominantly affects elderly patients. The aging population and technological advancements in immunofluorescence and proteomics technologies will further enhance the rheumatoid arthritis diagnosis influencing the segment growth.
The rising prevalence of diseases such as rheumatoid arthritis and Hashimoto’s thyroiditis and the presence of favorable government regulations will significantly impact the autoimmune disease diagnostics market growth. As per the Global RA Network, 2021, More than 350 million people have arthritis globally. The demand for better and more precise diagnostic methods, along with the increasing prevalence, is expected to increase over the forecast period.
Asia-Pacific is the Fastest Growing Region in the Autoimmune Disease Diagnostics Market
The COVID-19 pandemic significantly impacted the diagnosis of autoimmune diseases and clinical laboratory operations far beyond shortages of reagents and supplies. The increased workload forced laboratories to mobilize personnel and resources to support SARS-CoV-2 testing, affecting diagnostic testing of autoimmune diseases. Besides, people were also reluctant to visit the clinics and diagnostics centers during the 1stand 2nd wave of the coronavirus pandemic.
Asia-Pacific is anticipated to exhibit extensive market growth over the forecast period, owing to rising disposable income and increasing patient pool in emerging countries. Furthermore, growing awareness regarding the benefits of early and accurate diagnosis of autoimmune diseases to seek the proper treatment, rising development of healthcare infrastructure, and increasing healthcare expenditure are likely to boost the growth of the autoimmune disease diagnostics market in the Asia-Pacific region.
According to an article published by Janssen Asia Pacific, a division of Johnson & Johnson Pte. Ltd., autoimmune, inflammatory, and pulmonary diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are on the rise in the Asia Pacific. The region already has the world's highest burden of chronic obstructive pulmonary disease (COPD), as well as the highest prevalence of systemic lupus erythematosus (SLE) in China and Southeast Asia. Hence, this will likely create demand for diagnostics in the coming years.
Competitive Landscape
The Autoimmune Disease Diagnostics Market is fragmented and competitive. The market comprises significant market players, and these players are focusing on R&D activities and effective growth strategies. Recently, a few diagnostic companies entered into strategic partnerships with hospitals. This trend is expected to continue over the next few years to meet the high volume of patient needs across different regions.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Biomerieux
- Bio-rad Laboratories
- Euroimmun AG
- F. Hoffmann-la Roche
- Inova Diagnostics Inc.
- Myriad Genetics
- Siemens Healthineers Inc.
- Thermo Fisher Scientific
- Trinity Biotech
- Grifols, S.A.
- Exagen Inc.
- DIAsource ImmunoAssays SA
- R-Biopharm AG
Methodology
LOADING...
